Objective: To determine the in vitro chemosensitivity of feline injection siteassociated sarcoma (FISAS) cells to carboplatin concentrations generated by elution of carboplatin-impregnated calcium sulfate hemihydrate (CI-CSH) beads.
| I NT ROD UCTI ON
Feline injection site-associated sarcoma (FISAS) has been attributed to the subcutaneous administration of vaccines and other injectable medications to cats, occurring in up to 1/ 1000 vaccinated cats. 1, 2 The household cat population has been estimated to exceed 66 million cats in the United States and over 40% of these cats receive at least 1 vaccine per year, creating a sizable population at risk. [1] [2] [3] [4] Despite extensive research, the pathogenesis of FISAS has not been fully established. However, the most widely accepted theory implies a chronic inflammatory reaction at the site of an injection triggering subsequent malignant transformation of cells. [5] [6] [7] [8] 
FISAS cells have histological characteristics that are
Abbreviations: C-ICSH, carboplatin-impregnated calcium sulfate hemihydrate; FISAS, feline injection site-associated sarcoma; FSC-A, forward scatter; IC 50 , inhibitory concentration 50%; SSC-A, side scatter. The results of this study were presented in part at the American College of Veterinary Surgeons Surgical Summit, Seattle, WA, October 6-8, 2016. distinct from those of other spontaneously arising fibrosarcomas, such as perivascular infiltration of lymphocytes and macrophages at the periphery of the tumor, a central area of necrosis, high mitotic index, severe cellular pleomorphism, and granulation tissue at the periphery. 7, 9 These tumors are very challenging to treat, as they grow rapidly and invade surrounding tissues. 3, [6] [7] [8] [9] [10] [11] [12] Although distant metastasis affects 20%-28% of cats with FISAS, local recurrence of the tumor is the greatest cause of mortality, reported in 14%-45% of cats following complete excision and up to 70% of cats after incomplete excision of the tumor. [10] [11] [12] [13] [14] [15] [16] [17] Radical surgical excision of the tumor offers the best prognosis, but often requires thoracic or abdominal wall excision, amputation, or hemipelvectomy, or removal of the scapula or dorsal spinous processes. 12 Although the addition of radiation therapy improves the prognosis, many cats do not receive radical surgery and radiation therapy due to cost, invasiveness, or lack of access to a veterinary specialist. [14] [15] [16] [17] Unfortunately, most tumors recur within 1-2 years of treatment and are uniformly fatal.
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Carboplatin is a platinum-containing chemotherapeutic agent with similar anti-neoplastic efficacy than cisplatin, but less nephrotoxicity and emetogenicity. [18] [19] [20] [21] [22] Carboplatin has been evaluated for use in tumor-bearing cats and has shown some efficacy against FISAS, when given systemically. 19 The dose of carboplatin recommended to treat tumor-bearing cats is 240 mg/m 2 intravenously every 3-4 weeks. However, the recommended dosages for carboplatin are currently dictated by the systemic maximally tolerated dosage, body surface area, or glomerular filtration rate, rather than targeted tumor tissue concentrations. 22, 23 Local administration of cisplatin and carboplatin has been studied as a strategy to decrease systemic toxicity. [24] [25] [26] [27] [28] [29] Carboplatin-impregnated CSH (CI-CSH) beads are a commercially available delivery system (Wedgewood Pharmacy, Swedesboro, New Jersey) for sustained release of carboplatin following implantation at sites of gross tumor or of marginal tumor extirpation. Preliminary studies have reported that platinum is released predictably from CI-CSH beads for 22-30 days. 30, 31 Results from these studies provided estimations of the minimum and maximum platinum concentrations expected to elute from CI-CSH beads in vivo. 31 Calcium sulfate hemihydrate is a proven biodegradable carrier for drug release and causes minimal reaction in tissues. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] However, before CI-CSH beads can be recommended for use in tumorbearing cats, the efficacy of CI-CSH beads against FISAS cells, and the safety and efficacy of CI-CSH beads in cats must be determined. In vitro susceptibility testing of chemotherapeutics is a rapid way to determine the efficacy of a drug prior to administration. [43] [44] [45] [46] Only 3 veterinary studies have evaluated the concentration of carboplatin that inhibits 50% of growth (IC 50 ) of tumor cells in culture, including canine transitional cell carcinoma, melanoma, and mammary carcinoma cells. [44] [45] [46] To date, the concentration of carboplatin required to inhibit 50% growth of FISAS cells in vitro has not been determined. Although the in vitro chemosensitivity of other chemotherapeutic agents have been evaluated, none were evaluated in combination with a sustained-release local delivery system. In these studies, the ability of systemic administration to achieve therapeutic concentrations without toxicity in cats remained unclear. [47] [48] [49] The first objective of the study was to evaluate the antiproliferative potency of carboplatin against FISAS cells by determining the 50% inhibitory concentration (IC 50 ) and by apoptosis analysis. A second objective was to determine if IC 50 values were within the range of concentrations eluted from commercially available CI-CSH beads. We hypothesized that the IC 50 s of carboplatin against FISAS cells measured at 24 and 72 hours postexposure would fall within the range of concentrations of carboplatin known to elute from C-ICSH beads.
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2 | M ATE RI ALS AN D ME THOD S
| Cell lines and culture conditions
Five immortalized cell lines (ELA-1, Hamilton, Kaiser, Teitz, and Rose) derived from 5 histologically confirmed, primary FISAS tumors were generously provided (David Vail, University of Wisconsin). Cells were grown in continuous culture at 378C, 5% carbon dioxide in complete Dulbecco's modified of Eagle's medium (Mediatech Inc, Manassas, Virginia) supplemented with 10% fetal bovine serum (Mediatech Inc, Herndon, Virginia), and 1% penicillinstreptomycin (Thermo Fisher Scientific Inc, Waltham, Massachusetts) in 100 3 20 mm sterile culture dishes (Falcon; Corning Inc, Corning, New York). Confluent cells were subcultured every 6-7 days using a standard trypsinization process.
| Cell viability assay
The effects of carboplatin on FISAS cell viability were assessed using a bioreductive fluorometric assay (CellTiterBlue Cell Viability Assay; Promega Corporation, Madison, Wisconsin) according to instructions provided by the manufacturer. Immediately prior to initiating the study reported here, analyses of cell growth kinetics for all 5 cell lines were performed to determine the optimal concentration of cells that would maximize cell number without overcrowding wells or allowing the cells to outgrow their media before the 72-hour time point. Based on these analyses, 7.5 3 10 3 tumor cells were seeded per well and 3 wells were seeded for each carboplatin treatment using 96-well microplates (Falcon; Corning Inc). For cell culture experiments, a 96-well plate was prepared for each time point (24, 48 , and 72 hours) and, additionally, 3 independent replicates of the entire experiment were performed. The wells were not randomized in order to minimize errors, a protocol consistent with previously published methods. 44 
| Apoptosis analysis
For flow cytometric analysis, 3 of the FISAS cell lines with the highest proliferative potential were chosen for evaluation -ELA-1, Hamilton, and Kaiser (Table 2 ). Approximately 5 3 10 4 cells were plated per well and 3 wells were seeded for every carboplatin treatment using 6-well plates (Falcon; Corning Inc). A 6-well plate was prepared for each time point (24, 48 , and 72 hours) and, additionally, 3 independent replicates of the entire experiment were performed. Plates were incubated for 24 hours at 378C. Following incubation at time 0, culture media was removed and replaced with media containing 0, 5, 25, 75, 150, 300, and 450 mM concentrations of carboplatin. At 24, 48, and 72 hours after the addition of the carboplatin, the supernatant was collected from each corresponding plate and transferred to 5 mL round-bottom polystyrene tubes (Falcon; Corning Inc). Adherent viable cells were then subjected to a standard trypsinization process and were also collected. FISAS cell suspensions were centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and the cell pellet was resuspended in 1.5 mL of Annexin V Binding Buffer (BD Biosciences, San Jose, California). Control and treated cells were stained using the Annexin V FITC Apoptosis Detection Kit (BD Biosciences) and analyzed with a flow cytometer (BD LSR II, BD Biosciences). Data were acquired using BD FACSuite software (BD Biosciences) and using the Annexin V FITC assay. Data were derived and were analyzed using a minimum of 50 000 cell events for every carboplatin treatment (0-450 lM), and the software automatically generated a report. FSC-A versus SSC-A plots were used for gating cells 
| Statistical analysis
The sample size selected for cell culture is based on alpha 5 0.05, power 5 0.80, an expected difference in apoptosis of 100 cells between the highest and lowest carboplatin concentrations, and a standard deviation of 50 cells for each group. IC 50 values were computed for inhibitory doseresponse data using a nonlinear variable slope model procedure preprogrammed in Graph Pad Prism 7 (GraphPad Software, Inc, La Jolla, California). Measured response values (R) for each cell line and replicate were independently normalized using Y 5 min R/(max R -min R). Dose concentrations were log10-transformed (X). As described in the GraphPad 7 documentation, 50 the nonlinear Hill Slope and IC 50 were estimated for each cell line and replicate using the relationship: 
| R ES ULT S
Carboplatin induced both dose-dependent and timedependent decreases in the viability of FISAS cells ( Figure  1 lines at all time points were within the range of carboplatin eluted from CI-CSH beads in preliminary studies. 30, 31 Flow cytometric analysis of treated and untreated cells from 3 cell lines confirmed a dose-dependent effect of carboplatin on apoptosis of FISAS cells. Figure 2 shows a representative dose-response plot with Annexin V FITC-A versus PI-A. In the untreated control sample, the majority (90.7%) of cells were viable and nonapoptotic. Treatment with increasing concentrations of carboplatin resulted in decreases in viable cells (Annexin V-/PI-) and increases in cells undergoing early apoptosis (Annexin V1/PI-cells) and late apoptosis/necrosis (Annexin V1/PI1 cells) (Figure 2 ). Annexin V-/PI1 cells were categorized as fragmented nuclei.
| D IS C US S I ON
Treatment with carboplatin resulted in both dose-dependent and time-dependent decreases in cell viability of cultured FISAS cells. In carboplatin-treated wells, the proportion of nonviable cells was substantially increased 72 hours after exposure to carboplatin compared to control wells.
In a preliminary evaluation of in vitro elution of CI-CSH beads from the same manufacturer (Wedgewood Pharmacy), 2 sampling methods were employed to mimic different wound environments. Method 1 involved complete exchange of eluent at every time point to simulate a wound environment with rapid and complete extracellular fluid exchange. This method would determine the minimum concentration of carboplatin that would be expected to occur in vivo. Method 2 involved no exchange of eluent, thereby simulating a wound environment with negligible fluid exchange. This method would evaluate the cumulative release of carboplatin into the surrounding medium over time and the maximum concentration of carboplatin that would be expected to occur in vivo. Because wounds or tumor beds will vary among dogs and cats in size, vascularity, severity of inflammation, and rate and proportion of wound fluid exchange, it was concluded that the actual concentration of carboplatin eluted in vivo from CI-CSH beads should fall within the range of the reported minimum and maximum in vitro concentrations (Figure 3) . 31 Inhibitory concentration 50% values in the present study were within the range of carboplatin concentrations shown to elute from CI-CSH beads in the preliminary study, 31 indicating that carboplatin elutes sufficiently from CI-CSH beads to result in 50% growth inhibition of FISAS cells in culture. Mean concentrations of carboplatin eluted per bead at 24 and 72 hours in the preliminary study were 4 and 80 times the maximum 24-and 72-hour IC 50 values for carboplatin obtained in the present study against any FISAS cell line ( Figure 3) . 31 These data indicate implantation of only one CI-CSH bead may be sufficient to result in 50% inhibition of growth of FISAS cells in vivo. 31 Cisplatin and carboplatin delivery systems based on substrates such as open-cell polylactic acid (OPLA-Pt), hyaluronic acid, and others have been found effective against canine appendicular osteosarcoma, nasal tumors, and soft tissue sarcomas. 20, [25] [26] [27] [28] [29] However, these substrates are not commercially available, have shown unacceptable local toxicity 
F IGUR E 2 Representative Annexin V FITC-A versus Propidium
Iodide-A contour plots from untreated cells and cells treated with 450 lM carboplatin [25] [26] [27] [28] 32 In contrast, CSH beads are biocompatible and biodegradable, with minimal local reactivity and rare to no systemic toxicity. 28, 29, [38] [39] [40] Based on previous studies and results of the present study, implantation of CI-CSH beads may improve survival by delivering high concentrations of carboplatin directly to the site of greatest need, the extirpated tumor bed. 30, 31 In vivo efficacy of a local chemotherapy delivery system depends not only on the concentration of chemotherapy released, but also on diffusion of the agent in tissues. The spatial distribution of carboplatin released from CI-CSH beads in a tissue has not been reported. The manufacturer suggests that beads be implanted every 2 cm within a wound bed, but this recommendation is not substantiated by experimental data. 24 Although our results suggest that implantation of one bead every 2 cm in a wound bed would result in greater than 50% inhibition of FISAS cells, further studies are needed to characterize the 3-dimensional diffusion of carboplatin from CI-CSH beads implanted in vivo. Limitations of our in vitro study include the exposure times of 24, 48, and 72 hours, which do not necessarily correspond to the duration during which carboplatin concentrations may be maintained locally in vivo. Additional factors including tumor blood flow, drug metabolism, and the host and tumor immune responses may alter concentrations and efficacy of a chemotherapeutic agent. 48 50 value at that time point compared to the 24-hour time point. Furthermore, one study reported that certain cell line-specific responses characterize more aggressive neoplastic phenotypes and potential resistance to chemotherapy. 48 Finally, although the FISAS cell lines evaluated in the present study were historically established, repeated passages may affect clonal expansion and influence our results. Immortal cells can be passaged frequently, however, without affecting their growth cycles and characteristics with careful maintenance. 52 One study detected no difference in spontaneous proliferation rate between 2 FISAS cell lines across storage and culture conditions, when standard techniques were applied. 52 In conclusion, administration of carboplatin had significant dose-and time-dependent inhibitory effects on the viability of FISAS cells in culture and induced apoptosis in a majority of cells by 72 hours. The IC 50 of each FISAS cell F IGUR E 3 IC 50 values were within the range of carboplatin concentrations shown to elute from CI-CSH beads in preliminary studies. 31 CI-CSH, carboplatin impregnated-calcium sulfate hemihydrate; IC 50 , inhibitory concentration 50% line was within the reported range of elution of CI-CSH beads. 31 Local tumor control may therefore be achieved by implantation of as few as one CI-CSH bead immediately after radical excision of the primary tumor. Additionally, recurrent tumors may be treated minimally invasively by simple implantation of beads without tumor resection, or by marginal excision of larger tumors with concurrent bead implantation. Although these results show promise for the use of CI-CSH beads in cats with FISAS, further studies are needed to develop dosing recommendations for bead use in a clinical setting. We are currently evaluating the spatial distribution of carboplatin from CI-CSH beads in vitro as well as the pharmacokinetic and safety profile of CI-CSH beads administered subcutaneously to healthy cats.
